Business Wire

Kymeta Appoints New Sales Executives in Move to Build Global Sales Force

Share

Kymeta—the communications company making good on the promise of global, mobile connectivity—today announced the appointment of Rash Jhanjee to Vice President of Sales, EMEA (Europe, Middle East, and Africa) & Indian Subcontinent, Paul Mattear to Vice President of Sales and Business Development, and Scott Glass to Sales Director.

Kymeta recognizes the appointment of Mattear, Jhanjee and Glass as a critical move that will support the global growth and accessibility of Kymeta solutions across multiple markets. Kymeta’s focus on its global sales force will help the company serve both commercial and government customers.

Jhanjee—who joined Kymeta in August 2018—brings more than 20 years of experience in global strategic business development and sales with a specific emphasis on EMEA and Asia. Having previously held EMEA sales leadership positions with Loral Cyberstar, Stratos, VT iDirect, O3B Networks, Intelsat Africa Limited, and Arabsat, Jhanjee will focus on development and support for Kymeta’s EMEA and Indian Subcontinent customers. In one of Jhanjee’s recent roles with Inmarsat, he was responsible for market development of the Global Xpress program across various mobility verticals. Jhanjee holds academic credentials in Business Information Systems from the University of Portsmouth.

Mattear—who joined Kymeta in June 2018— brings over 27 years of experience in government and commercial satellite communications. Mattear served 22 years in the United States Marine Corps (USMC), where he held senior command positions and culminated his carrier at the White House Communications Agency. Prior to Kymeta, Mattear held senior leadership and management positions at Intelsat (North American broadband and mobility) and Intelsat General (Government Network Solutions), where he created satellite network communications solutions and business development opportunities for commercial and government customers. Mattear holds an MBA in Business and an MS (Master of Science) in Telecommunications Systems from the University of Maryland University College. He also holds an MMS (Master of Military Studies) from the Marine Corps University.

Glass—who joined Kymeta in June 2018—brings nearly 30 years of experience in sales and business development for network solutions. He has held senior positions at several notable companies including NetApp, Nokia, Foundry Networks (Brocade), and VT iDirect. Most recently, Glass provided sales leadership in networking solutions for remote location, business continuity, mobility and cellular backhaul for VT iDirect commercial maritime, energy, and service provider customers. Glass holds a bachelor’s degree in Computer Applications from the University of Houston, Clear Lake.

“The addition of Rash, Paul, and Scott to the Kymeta team comes at a pivotal time in our growth,” said David Harrower, Senior Vice President, Global Sales, Kymeta, “We are focused on developing a global sales-driven organization, and with these appointments, we are building the sales force required to support our commercial and government customers across all regions. This team will allow us to maximize every opportunity and enable Kymeta solutions for new markets.”

About Kymeta

The world’s demand for ubiquitous mobile connectivity is irrefutable. A global, mobile network is the answer to connecting people and places that have never been connected before.

Kymeta is making seamless, always-connected mobile communications possible with a unique hybrid approach that enables satellite and cellular networks to deliver a single, global, mobile network. End-to-end mobile communications are delivered with Kymeta KĀLO™ connectivity services, and the world’s first and only electronically-steered, flat-panel satellite terminal that goes places traditional satellite dishes cannot. The Kymeta KyWay™ terminal makes high-throughput, mobile communications possible in cars, trains, buses, trucks, boats, and much more.

If it moves, Kymeta keeps it connected.

For more information, visit kymetacorp.com and KALO.net.

Contact information

Business Inquiries for Kymeta:
Sam Christensen
Marketing
Kymeta Corporation
+1 425.658.8703
schristensen@kymetacorp.com
or
Media Inquiries for Kymeta:
Amy Oliver
PR/Content Manager
The Summit Group
+1 801.990.1185
aoliver@summitslc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leuke

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 14:57:00 EESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom